How Does Levetiracetam Work? Mechanism of Action Explained in Plain English

Levetiracetam (Keppra) works in a completely different way from most older seizure medications. While drugs like phenytoin, carbamazepine, and valproic acid target sodium channels or GABA receptors—pathways that have been known for decades—levetiracetam acts through a novel mechanism that wasn't fully understood at the time of its approval. Here's the plain-English explanation.

First, How Do Seizures Happen?

A seizure occurs when neurons (brain cells) fire abnormally and in a highly synchronized pattern. The brain has natural "braking" systems to prevent runaway electrical activity, but in epilepsy, those brakes aren't working properly—either because there's too much excitatory signaling, too little inhibitory signaling, or both.

Traditional antiepileptic drugs work by directly blocking these excitatory signals or boosting inhibitory ones. Levetiracetam takes a different approach.

The SV2A Mechanism: What Makes Levetiracetam Unique

Levetiracetam's primary target is a protein called SV2A — the synaptic vesicle glycoprotein 2A. Here's why that matters:

In neurons, chemical messages are sent across synapses (the gaps between nerve cells) using neurotransmitters stored in tiny packets called synaptic vesicles. When a neuron fires, these vesicles fuse with the cell membrane and release their neurotransmitter contents into the synapse. The SV2A protein helps regulate this fusion and release process.

By binding to SV2A, levetiracetam modulates how vesicles release neurotransmitters—particularly during rapid, high-frequency firing (which is exactly what happens in a seizure). In other words, it acts like a governor on an overheating engine, selectively dampening the abnormal, synchronized bursts of activity without broadly suppressing normal brain function.

What Levetiracetam Does NOT Do

This is actually one of the most remarkable aspects of levetiracetam's pharmacology. Unlike virtually every other AED on the market at the time of its 1999 approval, levetiracetam:

• Does NOT block voltage-dependent sodium channels (the target of phenytoin, carbamazepine, lamotrigine)
• Does NOT affect GABA receptors or potentiate GABAergic transmission (the target of benzodiazepines, barbiturates, valproate)
• Does NOT bind to glutamate receptors (the target of topiramate and others)

This distinct mechanism explains why levetiracetam works for patients who don't respond to other AEDs—it's targeting a completely different part of the seizure circuit.

Levetiracetam Also Inhibits Presynaptic Calcium Channels

Beyond SV2A, research has shown that levetiracetam also inhibits presynaptic calcium channels (specifically N-type and P/Q-type channels). Calcium influx is a critical trigger for neurotransmitter release. By reducing calcium entry at the presynaptic terminal, levetiracetam provides an additional brake on excessive neurotransmission during seizure activity.

Why This Mechanism Has Practical Advantages

The SV2A/presynaptic mechanism translates into several practical clinical advantages:

• Few drug interactions: Because levetiracetam is not metabolized by the liver's cytochrome P450 system and is less than 10% protein-bound, it doesn't interact with the dozens of drugs that affect these pathways. This makes it much easier to combine with other medications.
• Predictable pharmacokinetics: Bioavailability is close to 100%, unaffected by food, and the drug reaches steady-state in just 2 days. This makes dosing predictable and reliable.
• No hepatic metabolism: Only 2.5% of levetiracetam is metabolized by the liver. This makes it generally safer for patients with liver disease (though renal function must be monitored, as 66% is excreted unchanged by the kidneys).

What We Still Don't Know

Despite decades of research, the full molecular basis for levetiracetam's antiepileptic effect remains incompletely understood. The FDA's prescribing information explicitly states that "the precise mechanism(s) by which levetiracetam exerts its antiepileptic effect is unknown." The SV2A interaction is widely accepted as playing a major role (as of 2024), but exactly how this leads to seizure suppression at the cellular and circuit level is still an active area of research.

Brivaracetam: The Next-Generation SV2A Drug

Brivaracetam (Briviact), approved in 2016, was specifically designed to improve upon levetiracetam by achieving higher affinity binding to SV2A and more selective action. Clinical trials suggest it may cause fewer behavioral side effects (irritability, aggression) than levetiracetam, though its overall efficacy for seizure control is broadly similar.

Wondering how to find levetiracetam at a pharmacy near you? Use medfinder. Or read our overview: What Is Levetiracetam? Uses, Dosage, and What You Need to Know.